Physician profile
Mark C Mcgannon
NPI 1538275961
$1,288.99
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.43 · 2020: $65.80 · 2021: $334 · 2022: $298 · 2023: $494 · 2024: $22.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.92 | 2022-2024 | |
| Alcon Vision LLC | $148.89 | 2022-2023 | Clareon, Rocklatan |
| Horizon Therapeutics Plc | $121.60 | 2021-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $110.70 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.54 | 2020-2021 | |
| New World Medical,INC. | $86.16 | 2022-2023 | |
| Allergan, INC. | $68.01 | 2019-2021 | |
| Thea Pharma INC. | $47.71 | 2023 | Iyuzeh |
| Glaukos Corporation | $46.32 | 2022 | |
| Aerie Pharmaceuticals, INC. | $43.18 | 2021 | |
| Oyster Point Pharma, INC. | $39.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.94 | 2019 | |
| Bausch & Lomb Americas INC. | $21.55 | 2023 | Miebo |
| Rayner Intraocular Lenses Limited | $19.57 | 2023 | Rayone Aspheric, Rayone Spheric, Omidria |
| Mallinckrodt Enterprises LLC | $19.32 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $16.94 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcgannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.